Kronik Ağrıda Kök Hücre Tedavisi
Özet
Kök hücreler, farklı hücre tiplerine dönüşebilme ve kendini yenileme yetenekleri sayesinde kronik ağrı yönetiminde devrim niteliğinde bir alternatif sunmaktadır. Özellikle yağ dokusu kaynaklı mezenşimal kök hücreler (MKH), elde edilme kolaylığı ve düşük immün reaksiyon riski nedeniyle klinik uygulamalarda öne çıkmaktadır. MKH'ler, doğrudan doku onarımı, antiinflamatuar sitokin salınımı ve immün modülatör etkiler aracılığıyla iyileşme sağlar. Nöropatik ağrı, diyabetik nöropati ve trigeminal nevralji gibi geleneksel tedavilere dirençli durumlarda kök hücre nakli, sadece semptomatik rahatlama sağlamakla kalmaz, aynı zamanda sinir sistemini onarıcı etkiler gösterir. Hızlı başlangıçlı ve 90 güne kadar sürebilen uzun süreli antiallodinik etkileri, bu yöntemi cerrahi ve farmakolojik tedavilerin önüne geçirmektedir. Bununla birlikte, hücre kültürlerindeki tekrarlayan işlemlerin tedavi edici etkiyi azaltabileceği ve potansiyel tümörojenik riskler taşıyabileceği unutulmamalıdır. Sonuç olarak, kök hücre tedavisi toplum sağlığını ve sağlık harcamalarını iyileştirme potansiyeline sahip, gelecek vaat eden bir disiplindir.
Stem cells offer a revolutionary alternative in chronic pain management due to their ability to differentiate into various cell types and self-renew. Adipose-derived mesenchymal stem cells (MSCs), in particular, stand out in clinical applications due to their ease of acquisition and low risk of immune reaction. MSCs facilitate healing through direct tissue penetration, release of anti-inflammatory cytokines, and immunomodulatory effects. In cases resistant to traditional treatments such as neuropathic pain, diabetic neuropathy, and trigeminal neuralgia, stem cell transplantation not only provides symptomatic relief but also demonstrates restorative effects on the nervous system. Its rapid onset and long-lasting antiallodynic effects, which can persist for up to 90 days, position this method ahead of surgical and pharmacological alternatives. However, it should be noted that repeated procedures in cell cultures may diminish therapeutic efficacy and carry potential tumorigenic risks. In conclusion, stem cell therapy is a promising discipline with the potential to improve public health and healthcare expenditures.
Referanslar
Mao Q, Nguyen PD, Shanti RM, et al. Gingiva-Derived Mesenchymal Stem Cell-Extracellular Vesicles Activate Schwann Cell Repair Phenotype and Promote Nerve Regeneration. Tissue Eng Part A. 2019;25(11-12):887-900.
In ’t Anker PS, Scherjon SA, Kleijburg-van der Keur C, et al. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells Dayt Ohio. 2004;22(7):1338-45.
Bieback K, Kern S, Klüter H, et al. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells Dayt Ohio. 2004;22(4):625-34.
Padda J, Khalid K, Zubair U, et al. Stem Cell Therapy and Its Significance in Pain Management. Cureus. 2021;13(8):e17258.
Han YH, Kim KH, Abdi S, et al. Stem cell therapy in pain medicine. Korean J Pain. 2019;32(4):245-55.
Glenn JD, Whartenby KA. Mesenchymal stem cells: Emerging mechanisms of immunomodulation and therapy. World J Stem Cells. 2014;6(5):526-39.
Joshi HP, Jo H-J, Kim Y-H, et al. Stem Cell Therapy for Modulating Neuroinflammation in Neuropathic Pain. Int J Mol Sci. 2021;22(9):4853.
Bouhassira D. Neuropathic pain: Definition, assessment and epidemiology. Rev Neurol (Paris). 2019;175(1-2):16-25.
Garland EL. Pain Processing in the Human Nervous System: A Selective Review of Nociceptive and Biobehavioral Pathways. Prim Care. 2012;39(3):561-71.
Siniscalco D, Giordano C, Galderisi U, et al. Long-Lasting Effects of Human Mesenchymal Stem Cell Systemic Administration on Pain-Like Behaviors, Cellular, and Biomolecular Modifications in Neuropathic Mice. Front Integr Neurosci. 2011;5:79.
Hylands-White N, Duarte RV, Raphael JH. An overview of treatment approaches for chronic pain management. Rheumatol Int. 2017;37(1):29-42.
Varshney V, Osborn J, Chaturvedi R, et al. Advances in the interventional management of neuropathic pain. Ann Transl Med. 2021;9(2):187.
Rosenberger DC, Blechschmidt V, Timmerman H, et al. Challenges of neuropathic pain: focus on diabetic neuropathy. J Neural Transm Vienna Austria. 2020;127(4):589-624.
Alexander GM, van Rijn MA, van Hilten JJ, et al. Changes in cerebrospinal fluid levels of pro-inflammatory cytokines in CRPS. Pain. 2005;116(3):213-9.
Szok D, Tajti J, Nyári A, et al. Therapeutic Approaches for Peripheral and Central Neuropathic Pain. Behav Neurol. 2019;2019:8685954.
Ossipov MH. Growth factors and neuropathic pain. Curr Pain Headache Rep. 2011;15(3):185-92.
Meirelles L da S, Fontes AM, Covas DT, et al. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. 2009;20(5-6):419-27.
Ghannam S, Bouffi C, Djouad F, et al. Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Res Ther. 2010;1(1):2.
Vadivelu S, Willsey M, Curry DJ, et al. Potential role of stem cells for neuropathic pain disorders. Neurosurg Focus. 2013;35(3):E11.
Liu W, Yu F, Zhou Z, et al. Autologous Bone Marrow-Derived Stem Cells for Treating Diabetic Neuropathy in Metabolic Syndrome. BioMed Res Int. 2017;2017:8945310.
Pop-Busui R, Ang L, Holmes C, et al. Inflammation as a Therapeutic Target for Diabetic Neuropathies. Curr Diab Rep. 2016;16(3):29.
Kim H, Park J, Choi YJ, et al. Bone marrow mononuclear cells have neurovascular tropism and improve diabetic neuropathy. Stem Cells Dayt Ohio. 2009;27(7):1686-96.
Han JW, Sin MY, Yoon Y-S. Cell therapy for diabetic neuropathy using adult stem or progenitor cells. Diabetes Metab J. 2013;37(2):91-105.
Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther J Am Soc Gene Ther. 2012;20(1):14-20.
Koopman JSHA, Dieleman JP, Huygen FJ, et al. Incidence of facial pain in the general population. Pain. 2009;147(1-3):122-7.
Vickers ER, Karsten E, Flood J, et al. A preliminary report on stem cell therapy for neuropathic pain in humans. J Pain Res. 2014;7:255-63.
Sacerdote P, Niada S, Franchi S, et al. Systemic administration of human adipose-derived stem cells reverts nociceptive hypersensitivity in an experimental model of neuropathy. Stem Cells Dev. 2013;22(8):1252-63.
Sarugaser R, Hanoun L, Keating A, et al. Human mesenchymal stem cells self-renew and differentiate according to a deterministic hierarchy. PloS One. 2009;4(8):e6498.
Rubio D, Garcia S, Paz MF, et al. Molecular characterization of spontaneous mesenchymal stem cell transformation. PloS One. 2008;3(1):e1398.
Djouad F, Plence P, Bony C, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood. 2003;102(10):3837-44.
